Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zeta-MBC-005
- Development stage
- Preclinical
- Lead developer
- ZetaGen
- Modality
- Hydrogel Systems → Drug Delivery Systems, Small Molecules
- Administration
- Intralesional, Intrahepatic
01
Overview
Zeta-MBC-005 (also known as ZetaMAST) is a proprietary injectable drug-eluting hydrogel carrier developed by Zetagen Therapeutics for the locoregional treatment of unresectable, multifocal breast cancer metastases to the liver. The hydrogel is designed for controlled release of small molecule tumoricidal agents directly at metastatic sites in the liver. Preclinical studies have demonstrated that two concentrations of Zeta-MBC-005 significantly reduced tumor burden and increased survival rates compared to doxorubicin in mouse models with triple-negative breast cancer (TNBC) liver metastases. The therapy aims to address an unmet need in patients with metastatic breast cancer involving the liver—a population with poor prognosis and limited curative options—by providing local control and potential systemic biological effects. As of June 2025, it remains in preclinical development with plans for a Phase 1b clinical trial.
- Brand names
- ZetaMAST
- Other names
- Zeta-MBC-005Zeta-MBC005Zeta-MBC 005ZetaMASTzetaX005zetaX-005zetaX 005
Beyond the preview
Go deeper on Zeta-MBC-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zeta-MBC-005.